V
Vasileios Oikonomou
Researcher at National Institutes of Health
Publications - 7
Citations - 479
Vasileios Oikonomou is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Autoantibody & Immune system. The author has an hindex of 3, co-authored 7 publications receiving 194 citations.
Papers
More filters
Journal ArticleDOI
An immune-based biomarker signature is associated with mortality in COVID-19 patients.
Michael S. Abers,Ottavia M. Delmonte,Emily Ricotta,Jonathan Fintzi,Danielle Fink,Adriana Almeida de Jesus,Kol A. Zarember,Sara Alehashemi,Vasileios Oikonomou,Jigar V. Desai,Scott W. Canna,Bita Shakoory,Kerry Dobbs,Luisa Imberti,Alessandra Sottini,Eugenia Quiros-Roldan,Francesco Castelli,Camillo Rossi,Duilio Brugnoni,Andrea Biondi,Laura Rachele Bettini,Mariella D'Angiò,Paolo Bonfanti,Riccardo Castagnoli,Daniela Montagna,Amelia Licari,Gian Luigi Marseglia,Emily F. Gliniewicz,Elana Shaw,Dana Kahle,Andre Rastegar,Michael Stack,Katherine Myint-Hpu,Susan L Levinson,Mark J. DiNubile,Daniel W. Chertow,Peter D. Burbelo,Jeffrey I. Cohen,Katherine R. Calvo,John S. Tsang,Helen C. Su,John I. Gallin,Douglas B. Kuhns,Raphaela Goldbach-Mansky,Michail S. Lionakis,Luigi D. Notarangelo +45 more
TL;DR: Levels of sST2, sTNFRSF1A, IL-10, and IL-15 were consistently higher throughout the hospitalization in patients who died versus those who recovered, suggesting that these biomarkers may provide an early warning of eventual disease outcome.
Journal ArticleDOI
CARD9+ microglia promote antifungal immunity via IL-1β- and CXCL1-mediated neutrophil recruitment
Rebecca A. Drummond,Rebecca A. Drummond,Muthulekha Swamydas,Vasileios Oikonomou,Bing Zhai,Ivy M. Dambuza,Brian C. Schaefer,Andrea C. Bohrer,Katrin D. Mayer-Barber,Sergio A. Lira,Yoichir Iwakura,Scott G. Filler,Gordon D. Brown,Bernhard Hube,Bernhard Hube,Julian R. Naglik,Tobias M. Hohl,Michail S. Lionakis +17 more
TL;DR: Candidalysin is identified, a Candida virulence factor that elicits microglial expression of the cytokine IL-1β and chemokine CXCL1 and facilitates neutrophil recruitment and alteration of this pathway impairs antifungal responses.
Journal ArticleDOI
Aberrant type 1 immunity drives susceptibility to mucosal fungal infections.
Timothy J. Break,Vasileios Oikonomou,Nicolas Dutzan,Jigar V. Desai,Marc Swidergall,Marc Swidergall,Tilo Freiwald,Daniel Chauss,Oliver J. Harrison,Julie Alejo,Drake W. Williams,Stefania Pittaluga,Chyi-Chia Richard Lee,Nicolas Bouladoux,Muthulekha Swamydas,Kevin W. Hoffman,Teresa Greenwell-Wild,Vincent M. Bruno,Lindsey B. Rosen,Wint Lwin,Andy Renteria,Sergio M. Pontejo,John P. Shannon,Ian A. Myles,Peter Olbrich,Elise M. N. Ferré,Monica M. Schmitt,Daniel Martin,Daniel L. Barber,Norma V. Solis,Luigi D. Notarangelo,David V. Serreze,Mitsuru Matsumoto,Heather D. Hickman,Philip M. Murphy,Mark S. Anderson,Jean K. Lim,Steven M. Holland,Steven M. Holland,Scott G. Filler,Behdad Afzali,Yasmine Belkaid,Niki M. Moutsopoulos,Michail S. Lionakis +43 more
TL;DR: In this article, the authors identify aberrant T cell-dependent, type 1 mucosal inflammation as a critical tissue-specific pathogenic mechanism that promotes mucosal fungal infection susceptibility in mice and humans.
Journal ArticleDOI
Infections in the monogenic autoimmune syndrome APECED.
Vasileios Oikonomou,Timothy J. Break,Sarah L. Gaffen,Niki M. Moutsopoulos,Michail S. Lionakis +4 more
TL;DR: In this article, the authors discuss the expanding understanding of the immunological mechanisms that contribute to infection susceptibility in this prototypic syndrome of impaired central tolerance, which provide the foundation for devising improved diagnostic and therapeutic strategies for affected patients.
Posted ContentDOI
Multi-omics approach identifies novel age-, time- and treatment-related immunopathological signatures in MIS-C and pediatric COVID-19
Keith Sacco,Riccardo Castagnoli,Riccardo Castagnoli,Svetlana Vakkilainen,Can Liu,Ottavia M. Delmonte,Cihan Oguz,Ian M. Kaplan,Sara Alehashemi,Peter D. Burbelo,Farzana Bhuyan,Adriana Almeida de Jesus,Kerry Dobbs,Lindsey B. Rosen,Aristine Cheng,Elana Shaw,Mikko S. Vakkilainen,Francesca Pala,Justin B. Lack,Yu Zhang,Danielle Fink,Vasileios Oikonomou,Andrew L. Snow,Clifton L. Dalgard,Jinguo Chen,Brian Sellers,Gina A. Montealegre Sanchez,Karyl S. Barron,Emma Rey,Maria Cecilia Vial,María Cecilia Poli,Amelia Licari,Daniela Montagna,Gian Luigi Marseglia,Francesco Licciardi,Ugo Ramenghi,Valentina Discepolo,Andrea Lo Vecchio,Alfredo Guarino,Eli M. Eisenstein,Luisa Imberti,Alessandra Sottini,Andrea Biondi,Sayonara Mato,Dana Gerstbacher,Meng Truong,Michael Stack,Mary Magliocco,Marita Bosticardo,Tomoki Kawai,Jefffrey J. Danielson,Tyler Hulett,Manor Askenazi,Jeffrey I. Cohen,Helen C. Su,Douglas B. Kuhns,Michail S. Lionakis,Thomas M. Snyder,Steven M. Holland,Raphaela Goldbach-Mansky,John S. Tsang,Luigi D. Notarangelo +61 more
TL;DR: In this article, a longitudinal multi-institutional study was conducted to identify novel time and treatment-related immunopathological signatures in children with COVID-19 (n=105) and MIS-C, a multisystem inflammatory syndrome with significant morbidity.